# Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

> **NCT04215978** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 204 (actual)

## Conditions studied

- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Nasopharyngeal Carcinoma (NPC)

## Interventions

- **DRUG:** BGB-A445
- **DRUG:** tislelizumab

## Key facts

- **NCT ID:** NCT04215978
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-30
- **Primary completion:** 2025-01-24
- **Final completion:** 2025-01-24
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04215978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04215978, "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04215978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*